KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Assets (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Current Assets for 15 consecutive years, with $644.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 6.11% to $644.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $644.2 million, a 6.11% decrease, with the full-year FY2025 number at $644.2 million, down 6.11% from a year prior.
  • Current Assets was $644.2 million for Q4 2025 at Supernus Pharmaceuticals, up from $593.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $883.3 million in Q1 2023 to a low of $423.5 million in Q2 2023.
  • A 5-year average of $623.1 million and a median of $632.2 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 55.38% in 2023, then crashed 38.38% in 2024.
  • Supernus Pharmaceuticals' Current Assets stood at $601.6 million in 2021, then rose by 22.04% to $734.2 million in 2022, then plummeted by 32.83% to $493.1 million in 2023, then skyrocketed by 39.13% to $686.1 million in 2024, then decreased by 6.11% to $644.2 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Current Assets are $644.2 million (Q4 2025), $593.9 million (Q3 2025), and $738.9 million (Q2 2025).